Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2,691 INR | -0.12% | +5.97% | +16.72% |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
Strengths
- The earnings growth currently anticipated by analysts for the coming years is particularly strong.
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- The group's high margin levels account for strong profits.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
- The opinion of analysts covering the stock has improved over the past four months.
Weaknesses
- With an expected P/E ratio at 56.05 and 44.3 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
- Based on current prices, the company has particularly high valuation levels.
- The company appears highly valued given the size of its balance sheet.
- The valuation of the company is particularly high given the cash flows generated by its activity.
- The company is not the most generous with respect to shareholders' compensation.
Ratings chart - Surperformance
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+16.72% | 10.92B | - | ||
+25.83% | 661B | C+ | ||
+27.00% | 566B | B | ||
-6.76% | 352B | C+ | ||
+20.34% | 332B | B- | ||
+3.00% | 283B | C+ | ||
+13.09% | 231B | B+ | ||
+5.46% | 200B | B- | ||
-9.61% | 195B | A+ | ||
-6.26% | 145B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- TORNTPHARM Stock
- TORNTPHARM Stock
- Ratings Torrent Pharmaceuticals Limited